Diabetogenic T lymphocytes in human Type 1 diabetes

Current Opinion in Immunology

Volumn 23, Issue 6, 2011, Pages 746-753

  Roep, Bart O ^a   Peakman, Mark ^b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; HLA B ANTIGEN; INSULIN; INTERLEUKIN 17; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; DIABETOGENIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; PANCREAS ISLET BETA CELL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS; B-LYMPHOCYTES; CELL MOVEMENT; DIABETES MELLITUS, TYPE 1; HUMANS; T-LYMPHOCYTES;

EID: 82955247941     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.10.001     Document Type: Review

References (72)

1. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Marks J.B., Monzavi R., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
2. Bach J.F. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011, 378:459-460.
3. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
4. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
5. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.
6. Foulis A.K., Liddle C.N., Farquharson M.A., Richmond J.A., Weir R.S. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986, 29:267-274.
7. Willcox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009, 155:173-181.
8. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., Hors J., Mihatsch M.J., Paillard M., Chaussain J.L., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988, 318:663-670.
9. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
10. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., Vandemeulebroucke E., Van de Velde U., Crenier L., De Block C., et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53:614-623.
11. Voltarelli J.C., Couri C.E., Stracieri A.B., Oliveira M.C., Moraes D.A., Pieroni F., Coutinho M., Malmegrim K.C., Foss-Freitas M.C., Simoes B.P., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297:1568-1576.
12. Huurman V.A., Hilbrands R., Pinkse G.G., Gillard P., Duinkerken G., van de Linde P., van der Meer-Prins P.M., Versteeg-van der Voort Maarschalk M.F., Verbeeck K., Alizadeh B.Z., et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008, 3:e2435.
13. Di Lorenzo T.P., Peakman M., Roep B.O. Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007, 148:1-16.
14. Palmer J.P., Asplin C.M., Clemons P., Lyen K., Tatpati O., Raghu P.K., Paquette T.L. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983, 222:1337-1339.
15. Staeva-Vieira T., Peakman M., von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007, 148:17-31.
16. Baekkeskov S., Aanstoot H.J., Christgau S., Reetz A., Solimena M., Cascalho M., Folli F., Richter-Olesen H., DeCamilli P., Camilli P.D. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990, 347:151-156.
17. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
18. Wherrett D.K., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Herold K.C., Marks J.B., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378:319-327.
19. Payton M.A., Hawkes C.J., Christie M.R. Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 1995, 96:1506-1511.
20. Castano L., Russo E., Zhou L., Lipes M.A., Eisenbarth G.S. Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with type I diabetes. J Clin Endocrinol Metab 1991, 73:1197-1201.
21. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., Rewers M., Eisenbarth G.S., Jensen J., Davidson H.W., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104:17040-17045.
22. Delong T., Baker R.L., Reisdorph N., Reisdorph R., Powell R.L., Armstrong M., Barbour G., Bradley B., Haskins K. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes 2011, 60:2325-2330.
23. Stadinski B.D., Delong T., Reisdorph N., Reisdorph R., Powell R.L., Armstrong M., Piganelli J.D., Barbour G., Bradley B., Crawford F., et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010, 11:225-231.
24. Chamberlain J.L., Pittock S.J., Oprescu A.M., Dege C., Apiwattanakul M., Kryzer T.J., Lennon V.A. Peripherin-IgG association with neurologic and endocrine autoimmunity. J Autoimmun 2010, 34:469-477.
25. Peakman M., von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010, 59:2087-2093.
26. Velthuis J.H., Unger W.W., Abreu J.R., Duinkerken G., Franken K., Peakman M., Bakker A.H., Reker-Hadrup S., Keymeulen B., Drijfhout J.W., et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010, 59:1721-1730.
27. Roep B.O., Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 2010, 10:145-152.
28. Tsai S., Shameli A., Yamanouchi J., Clemente-Casares X., Wang J., Serra P., Yang Y., Medarova Z., Moore A., Santamaria P. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010, 32:568-580.
29. Buus S., Lauemoller S.L., Worning P., Kesmir C., Frimurer T., Corbet S., Fomsgaard A., Hilden J., Holm A., Brunak S. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003, 62:378-384.
30. Drijfhout J.W., Brandt R.M., D'Amaro J., Kast W.M., Melief C.J. Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Hum Immunol 1995, 43:1-12.
31. Dick T.P., Stevanovic S., Keilholz W., Ruppert T., Koszinowski U., Schild H., Rammensee H.G. The making of the dominant MHC class I ligand SYFPEITHI. Eur J Immunol 1998, 28:2478-2486.
32. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994, 152:163-175.
33. Fairchild P.J., Wildgoose R., Atherton E., Webb S., Wraith D.C. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. Int Immunol 1993, 5:1151-1158.
34. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I., et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008, 118:3390-3402.
35. Wucherpfennig K.W., Call M.J., Deng L., Mariuzza R. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr Opin Immunol 2009, 21:590-595.
36. Stadinski B.D., Zhang L., Crawford F., Marrack P., Eisenbarth G.S., Kappler J.W. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A 2010, 107:10978-10983.
37. Levisetti M.G., Lewis D.M., Suri A., Unanue E.R. Weak proinsulin peptide-major histocompatibility complexes are targeted in autoimmune diabetes in mice. Diabetes 2008, 57:1852-1860.
38. Levisetti M.G., Suri A., Petzold S.J., Unanue E.R. The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. J Immunol 2007, 178:6051-6057.
39. Ouyang Q., Standifer N.E., Qin H., Gottlieb P., Verchere C.B., Nepom G.T., Tan R., Panagiotopoulos C. Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes. Diabetes 2006, 55:3068-3074.
40. Unger W.W., Velthuis J., Abreu J.R., Laban S., Quinten E., Kester M.G., Reker-Hadrup S., Bakker A.H., Duinkerken G., Mulder A., et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun 2011, in press.
41. Sercarz E.E. Driver clones and determinant spreading. J Autoimmun 2000, 14:275-277.
42. Kent S.C., Chen Y., Bregoli L., Clemmings S.M., Kenyon N.S., Ricordi C., Hering B.J., Hafler D.A. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005, 435:224-228.
43. Dotta F., Censini S., van Halteren A.G., Marselli L., Masini M., Dionisi S., Mosca F., Boggi U., Muda A.O., Prato S.D., et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 2007, 104:5115-5120.
44. Velthuis J.H., Unger W.W., van der Slik A.R., Duinkerken G., Engelse M., Schaapherder A.F., Ringers J., van Kooten C., de Koning E.J., Roep B.O. Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia 2009, 52:494-503.
45. Roep B.O., Kleijwegt F.S., van Halteren A.G., Bonato V., Boggi U., Vendrame F., Marchetti P., Dotta F. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010, 159:338-343.
46. Lennon G.P., Bettini M., Burton A.R., Vincent E., Arnold P.Y., Santamaria P., Vignali D.A. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 2009, 31:643-653.
47. Foulis A.K., Farquharson M.A., Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987, 2:1423-1427.
48. Nejentsev S., Howson J.M., Walker N.M., Szeszko J., Field S.F., Stevens H.E., Reynolds P., Hardy M., King E., Masters J., et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007, 450:887-892.
49. Thomas H.E., Trapani J.A., Kay T.W. The role of perforin and granzymes in diabetes. Cell Death Differ 2010, 17:577-585.
50. Standifer N.E., Ouyang Q., Panagiotopoulos C., Verchere C.B., Tan R., Greenbaum C.J., Pihoker C., Nepom G.T. Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. Diabetes 2006, 55:3061-3067.
51. Mastrandrea L., Yu J., Behrens T., Buchlis J., Albini C., Fourtner S., Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009, 32:1244-1249.
52. Stassi G., De Maria R., Trucco G., Rudert W., Testi R., Galluzzo A., Giordano C., Trucco M. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997, 186:1193-1200.
53. Thomas H.E., Darwiche R., Corbett J.A., Kay T.W. Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. J Immunol 1999, 163:1562-1569.
54. Eizirik D.L., Colli M.L., Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009, 5:219-226.
55. Arif S., Moore F., Marks K., Bouckenooghe T., Dayan C.M., Planas R., Vives-Pi M., Powrie J., Tree T., Marchetti P., et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated {beta}-cell death. Diabetes 2011, 60:2112-2119.
56. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., Knip M., Otonkoski T., Vaarala O. IL-17 immunity in human type 1 diabetes. J Immunol 2010, 185:1959-1967.
57. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., Xu L., Priatel J.J., Levings M.K., Tan R. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 2010, 185:3814-3818.
58. Planas R., Carrillo J., Sanchez A., de Villa M.C., Nunez F., Verdaguer J., James R.F., Pujol-Borrell R., Vives-Pi M. Gene expression profiles for the human pancreas and purified islets in type 1 diabetes: new findings at clinical onset and in long-standing diabetes. Clin Exp Immunol 2010, 159:23-44.
59. Vukkadapu S.S., Belli J.M., Ishii K., Jegga A.G., Hutton J.J., Aronow B.J., Katz J.D. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 2005, 21:201-211.
60. van Halteren A.G., Kardol M.J., Mulder A., Roep B.O. Homing of human autoreactive T cells into pancreatic tissue of NOD-scid mice. Diabetologia 2005, 48:75-82.
61. Pinkse G.G., Tysma O.H., Bergen C.A., Kester M.G., Ossendorp F., van Veelen P.A., Keymeulen B., Pipeleers D., Drijfhout J.W., Roep B.O. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A 2005, 102:18425-18430.
62. Naik R.G., Beckers C., Wentwoord R., Frenken A., Duinkerken G., Brooks-Worrell B., Schloot N.C., Palmer J.P., Roep B.O. Precursor frequencies of T-cells reactive to insulin in recent onset type 1 diabetes mellitus. J Autoimmun 2004, 23:55-61.
63. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., Roep B.O., Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-463.
64. Tree T.I., Lawson J., Edwards H., Skowera A., Arif S., Roep B.O., Peakman M. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 2010, 59:1451-1460.
65. Tree T.I., Duinkerken G., Willemen S., de Vries R.R., Roep B.O. HLA-DQ-regulated T-cell responses to islet cell autoantigens insulin and GAD65. Diabetes 2004, 53:1692-1699.
66. Wong C.P., Stevens R., Long B., Li L., Wang Y., Wallet M.A., Goudy K.S., Frelinger J.A., Tisch R. Identical beta cell-specific CD8(+) T cell clonotypes typically reside in both peripheral blood lymphocyte and pancreatic islets. J Immunol 2007, 178:1388-1395.
67. Trudeau J.D., Kelly-Smith C., Verchere C.B., Elliott J.F., Dutz J.P., Finegood D.T., Santamaria P., Tan R. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003, 111:217-223.
68. Bevan M.J., Hogquist K.A., Jameson S.C. Selecting the T cell receptor repertoire. Science 1994, 264:796-797.
69. Jameson S.C., Bevan M.J. T-cell selection. Curr Opin Immunol 1998, 10:214-219.
70. Zehn D., Bevan M.J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006, 25:261-270.
71. Thrower S.L., James L., Hall W., Green K.M., Arif S., Allen J.S., Van-Krinks C., Lozanoska-Ochser B., Marquesini L., Brown S., et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009, 155:156-165.
72. Lissina A., Ladell K., Skowera A., Clement M., Edwards E., Seggewiss R., van den Berg H.A., Gostick E., Gallagher K., Jones E., et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 2009, 340:11-24.